Now you can access multiple body composition biomarkers and disease insights through a rapid MRI. Get to know AMRA's solutions for your clinical and research needs.
As healthcare advances in better understanding individual variability in genetics, lifestyle, and biology, body composition assessment often remains imprecise and impersonal.
AMRA is the game-changer. Rapid whole-body MRI and automated, cloud-based image analysis now allow you to monitor small, clinically relevant changes in fat and muscle volumes. Simple, safe, and cost-effective – you send us images; we give precise, individualized body composition measurements and contextual disease insights.
Data-driven trial optimization by advancing clinical research and its therapeutic application.
Providing medical insights to unlock breakthroughs within the field of precision medicine.
Supporting the prediction and prevention of disease and the availability of more informed personalized treatments.
"AMRA-derived body composition data enables us at Human Longevity Inc to integrate quantitative imaging results with genomic and clinical biomarkers to give our clients and their physicians a comprehensive evaluation of their risk for diabetes, cardiovascular disease and metabolic syndrome."
"By employing AMRA’s automated analysis, we are now able to efficiently provide more actionable data to our pharmaceutical partners."
"Working with AMRA ensures high-quality, accurate data acquisition in our clinical studies that will be used to transform patient care for the future."
"I am very impressed with the body composition analysis that AMRA offers. The system works well and we get valuable data in a fast way. I am very pleased with the extra opportunities this will provide us to further improve our scientific research. The people are great to work with and there is fast, good service"
"The partnership with AMRA makes it possible to get scan results produced at Scannexus and Maastricht UMC+ to researchers much faster. Researchers now have one point of contact for support with their research."
WEDNESDAY, OCTOBER 7, 2020 @ 11:00 AM - 12:30 PM EDT Drug development in neuromuscular disorders needs robust…
AMRA Medical assessed prevalence of sarcopenia, adverse muscle composition, and low functional performance within Type…
